The present invention provides a method for treating or delaying the onset of an autoimmune condition in a human subject. An effective oral dose of an anti-CD20 antibody is administered to the subject. Oral administration of such antibodies as rituximab, ocrelizumab, ofatumumab, obinutuzumab, tositumomab, or ibritumomab are useful in a method of decreasing innate inflammatory cytokines, such as and TNF-a, IFN-g, IL-17, and IL-12.
